Marangell L B, George M S, Bissette G, Pazzaglia P, Huggins T, Post R M
Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Md.
Arch Gen Psychiatry. 1994 Aug;51(8):625-8. doi: 10.1001/archpsyc.1994.03950080037005.
Thyrotropin-releasing hormone is an endogenous tripeptide with endocrine-independent neurophysiologic properties that may be relevant to affective or seizure disorders. We studied the effect of carbamazepine, which has both mood-stabilizing and anticonvulsant properties, on cerebrospinal fluid thyrotropin-releasing hormone levels in affectively ill patients.
Paired cerebrospinal fluid samples were collected from nine inpatients with mood disorders, both while medication free and while taking carbamazepine for an average of longer than 1 month at 950 mg/d, achieving blood levels of 8.8 mg/L.
Carbamazepine treatment was consistently and significantly associated with increased cerebrospinal fluid thyrotropin-releasing hormone levels (P < .0001).
As carbamazepine-induced increases in thyrotropin-releasing hormone levels could be relevant to either its psychotropic or anticonvulsant properties, further clinical and preclinical investigation of this finding appears indicated.
促甲状腺激素释放激素是一种内源性三肽，具有与内分泌无关的神经生理特性，可能与情感障碍或癫痫发作有关。我们研究了具有情绪稳定和抗惊厥特性的卡马西平对情感障碍患者脑脊液促甲状腺激素释放激素水平的影响。
从9名情绪障碍住院患者中采集配对的脑脊液样本，一次是在未用药时，另一次是在服用卡马西平平均超过1个月、剂量为950mg/d且血药浓度达到8.8mg/L时。
卡马西平治疗始终且显著地与脑脊液促甲状腺激素释放激素水平升高相关（P <.0001）。
由于卡马西平引起的促甲状腺激素释放激素水平升高可能与其精神otropic作用或抗惊厥特性有关，因此似乎有必要对这一发现进行进一步的临床和临床前研究。
